Enanta Pharmaceuticals to Host Conference Call on November 23 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal...
November 16 2020 - 6:02AM
Business Wire
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage
biotechnology company dedicated to creating small molecule drugs
for viral infections and liver diseases, today announced that it
plans to report its financial results for its fiscal fourth quarter
and year ended September 30, 2020 after the U.S. markets close on
November 23, 2020. Enanta management will host a conference call at
4:30 p.m. ET to discuss these results and provide an update on
Enanta’s business, including its research and development
pipeline.
Conference Call and Webcast Information To participate in
the live conference call, please dial 855-840-0595 in the U.S. or
518-444-4814 for international callers. A replay of the conference
call will be available starting at approximately 8:00 p.m. ET on
November 23, 2020, through 11:59 p.m. ET on November 28, 2020 by
dialing 855-859-2056 from the U.S. or 404-537-3406 for
international callers. The passcode for both the live call and the
replay is 5436807. A live audio webcast of the call and replay can
be accessed by visiting the “Events and Presentations” section on
the “Investors” page of Enanta’s website at www.enanta.com.
About Enanta Pharmaceuticals, Inc. Enanta is using its
robust, chemistry-driven approach and drug discovery capabilities
to become a leader in the discovery and development of small
molecule drugs for the treatment of viral infections and liver
diseases. Enanta’s research and development efforts have produced
clinical candidates for the following disease targets: respiratory
syncytial virus (RSV), non-alcoholic steatohepatitis (NASH) and
hepatitis B virus (HBV). Enanta is also conducting research in
human metapneumovirus (hMPV) and SARS-CoV-2 (COVID-19).
Enanta’s research and development activities are funded by
royalties from hepatitis C virus (HCV) products developed under its
collaboration with AbbVie. Glecaprevir, a protease inhibitor
discovered by Enanta, is sold by AbbVie in numerous countries as
part of its leading treatment for chronic HCV infection under the
tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.)
(glecaprevir/pibrentasvir). Please visit www.enanta.com for more
information.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201116005161/en/
Media and Investor Contact: Jennifer Viera 617-744-3848
jviera@enanta.com
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Apr 2024 to May 2024
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From May 2023 to May 2024